Pharmacotherapy after myocardial infarction: Disease management versus usual care

American Journal of Managed Care

Volumn 14, Issue 6, 2008, Pages 352-358

  Chan, Vicky ^a,c   Cooke, Catherine E ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b PosiHealth   (United States)

^c NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MENTAL COMPLIANCE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

CLINICAL PROTOCOLS; COHORT STUDIES; DISEASE MANAGEMENT; DRUG THERAPY; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES;

EID: 46449110081     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hunter DJ, Fairfield G. Disease management. BMJ. 1997;315(7099):50-53.
2. Ara S. A literature review of cardiovascular disease management programs in managed care organizations. J Manag Care Pharm. 2004;10(4):326-344.
3. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69-e171.
4. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001;38(5):1581-1583.
5. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2000;102(10):1193-1209.
6. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ. 2005;330(7499):1059-1063.
7. Simpson E, Beck C, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145(3):438-444.
8. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41(1):56-61.
9. EUROSPIRE I and II Group. Clinical reality of coronary prevention guidelines; a comparison of EUROSPIRE I and II in nine countries. Lancet. 2001;357(9261):995-1001.
10. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336(8714):542- 545.
11. McAlister FA, Lawson FM, Teo KK, Armstrong PW. Randomised trials of secondary prevention programmes in coronary heart disease: systemic review. BMJ. 2001;323(7319):957-962.
12. Ofman JJ, Badamgarav E, Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med. 2004;117(3):182-192.
13. Hedback B, Perk J, Wodlin P. Long term reduction of cardiac mortality after myocardial infarction: 10 year results of a comprehensive rehabilitation programme. Eur Heart J. 1993;14(6):831-835.
14. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8):1280-1288.
15. DeBusk RF, Miller NH, Superko RH, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120(9):721-729.
16. Whellan DJ, Cohen EJ, Matchar DB, Califf RM. Disease management in healthcare organizations: results of in-depth interviews with disease management decision makers. Am J Manag Care. 2002;8(7):633-641.
17. Landis D, Georgiou A, Apple J, Durand J. Cardiovascular risk reduction at UnitedHealthcare of North Carolina: the first 12 months. J Clin Outcomes Manag. 2000;7(4):40-43.
18. Etemand LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm. 2005;11(4):300-306.
19. Fitzner K, Fox K, Schmidt J, Roberts M, Rindress D, Hay J. Implementation and outcomes of commercial disease management programs in the United States: the disease management outcomes consolidation survey. Dis Manag. 2005;8(4):253-264.
20. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116.